Design Therapeutics, Inc. Common Stock (DSGN)
PHARMACEUTICAL PREPARATIONS
Design Therapeutics, Inc. Common Stock (DSGN) is listed on Nasdaq, where it has traded since March 26, 2021.
- Listed On
- Nasdaq
- Listed Since
- March 26, 2021
- Employees
- 55
- Market Cap
- $758M
About Design Therapeutics, Inc. Common Stock
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 133 institutions reported holding DSGN, with 43.3 million shares worth $626.4 million in aggregate. The largest reported holder was SR One Capital Management, with 6.5 million shares worth $94.4 million. Of the 5 largest holders listed below, 4 added shares and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| SR One Capital Management | 6,526,476 | $94M | Unchanged |
| Logos Global Management | 3,000,000 | $43M | Added 53.85% |
| Baker Bros. Advisors | 2,678,430 | $39M | Added 3.58% |
| Driehaus Capital Management | 2,661,115 | $39M | Added 52.5% |
| BlackRock | 2,660,024 | $38M | Added 24.66% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is DSGN?
Design Therapeutics, Inc. Common Stock (DSGN) is listed on Nasdaq, where it has traded since March 26, 2021.
Who are the largest institutional holders of DSGN?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of DSGN were SR One Capital Management, Logos Global Management and Baker Bros. Advisors.
How many institutions own DSGN?
133 institutions reported a position in DSGN for the quarter ended June 30, 2026, worth $626.4 million in total.
Did institutions buy or sell DSGN last quarter?
Of the 5 largest reported holders, 4 added shares and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for DSGN.
Every reported institutional holder, plus insider and congressional trades in DSGN, on SentiSense.